IDWeek 2021 Virtual Conference

Healix is once again a proud Bronze Sponsor for IDWeek 2021—the premier show for infectious diseases.  IDWeek is a forum for health professionals of varied backgrounds to collaborate, cooperate, and learn from each other’s expertise. With so many common issues and challenges across multiple disciplines, IDWeek provides an opportunity to learn from each colleague’s experience and expertise, for the improvement of patient care and public health.

IDWeek 2021 is a virtual event, from Sept. 29 to Oct. 3, 2021. 

IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medical Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP). For more information, visit IDWeek online.

Look for Healix throughout the IDWeek virtual platform and check out our article “Outpatient Infusion Care and the Physician Practice: A Collaborative Site of Care with Optimal Outcomes”.

From our long-standing involvement in the infectious disease community, Healix also coordinates and conducts collaborative clinical research in the provision of Outpatient Parenteral Antimicrobial Therapy (OPAT) since 2008. While attending the conference, please visit the following Healix poster presentations with presenter audio available beginning September 29 in the ePoster Gallery:

#597: The Impact of COVID-19 on Outpatient Intravenous Antimicrobial Therapy (OPAT) in Physician Office Infusion Centers (POICs)

Clifford P. Martin1, MD; Robin H. Dretler, MD2; Jorge R. Bernett, MD3; Barry Statner, MD, FRCPC, FIDSA4; Thomas K. Sleweon, MD5; Quyen Luu, MD6; Richard C. Prokesch, MD, FACP, FIDSA7; Kent J. Stock, DO8; Claudia P. Schroeder, PharmD, PhD9; Thomas C. Hardin, PharmD9; Lucinda J. Van Anglen, PharmD9

1Southern Arizona Infectious Disease Specialists, PLC, Tucson, AZ; 2Infectious Disease Specialists of Atlanta, PC, Decatur, GA; 3Infectious Disease Doctors Medical Group, APC, Walnut Creek, CA; 4Mazur, Statner, Dutta, Nathan, PC, Thousand Oaks, CA; 5Infectious Disease Specialists, Highland, IN; 6Central Georgia Infectious Diseases, LLC; Macon, GA; 7Infectious Diseases Associates, Riverdale, GA; 8Low Country Infectious Diseases, PA, Charleston, SC; 9Healix Infusion Therapy, LLC, Sugar Land, TX

#598: A 3-Year Evaluation of Antibiotic Resistance Patterns in Gram-Negative Genitourinary Tract Infections Treated in Outpatient Infusion Centers (POICs)

Richard L. Hengel, MD1; Brian S. Metzger, MD, MPH2; H. Barry Baker, MD, FACP3; John S. Adams, MD, FIDSA, FSHEA4; Ramesh V. Nathan, MD, FIDSA5; Rishi Bhattacharyya, MD6; Richard M. Mandel, MD, FIDSA7; Kimberly A. Couch, PharmD, MA, FIDSA, FASHP8; Claudia P. Schroeder, PharmD, PhD8; Lucinda J. Van Anglen, PharmD8

1Atlanta ID Group, Atlanta, GA; 2Austin Infectious Disease Consultants, Austin, TX; 3Infectious Disease Physicians, Miami, FL; 4Knoxville Infectious Disease Consultants, Knoxville, TN; 5Mazur, Statner, Dutta, Nathan, PC, Thousand Oaks, CA; 6Infectious Diseases Associates, Sarasota, FL; 7Southern Arizona Infectious Disease Specialists, Tucson, AZ; 8Healix Infusion Therapy, LLC, Sugar Land, TX



View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.